JAMA

ATS 2025: Are alpha-2 agonists the key to quicker ICU extubation?

May 23, 2025

Despite theoretical benefits of alpha-2 agonists, this trial didn’t find clinical advantage over propofol in facilitating extubation or improving ICU outcomes. Propofol remains the standard for primary sedation in mechanically ventilated ICU patients. These findings were simultaneously shared at the American Thoracic Society annual meeting and published in JAMA.

Study details: The Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B; NCT03653832) multicenter, open-label, randomized trial included 1,000 critically ill adults requiring mechanical ventilation for ≥48 hours. Patients were randomized to receive sedation based on dexmedetomidine, clonidine, or propofol. The primary outcome was time to successful extubation, defined as extubation followed by 48 hours of spontaneous breathing.

Results: Median time from randomization to successful extubation was 136 (95% confidence interval [CI], 117-150) hours for dexmedetomidine, 146 (95% CI, 124-168) hours for clonidine, and 162 (95% CI 136-170) hours for propofol. Neither alpha-2 agonist significantly improved extubation timing. Secondary outcomes, including ICU length of stay, mortality, and delirium incidence, also showed no significant differences.

Source:

Walsh TS, et al; A2B Trial Investigators. (2025, May 19). JAMA. Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40388916/